The aim of this study was to evaluate the hepatoprotective and anti-inflammatory effects of silybin-phospholipids and vitamin E complex (SPV complex), by determining cytokine patterns and various markers of liver disease.
Forty Caucasian patients with chronic HCV infection were recruited and divided into two groups:
• 30 were treated with SPV complex for 3 months,
• While the other 10 did not receive any treatment.
• Ten other subjects without HCV infection but with steatosic diagnosis were recruited and treated with SPV complex. [Steatosis – fatty deposits in the liver.]
Biochemical and hepatic principal parameters were investigated at 0 (T0) and 3 months (T3).
The group of HCV patients treated showed an improvement trend of hepatic indecises and viral load, and had a significant and persistent reduction of ALT (P = 0.02) and AST serum level (P = 0.01). In this group cytokines showed a statistically significant increase of IL-2 (P = 0.03) and IL-6 were significantly reduced (P = 0.02) at T0 and T3.
After the treatment the group of hepatic steatosics showed a significant decrease in ALT (P = 0.02), AST (0.008), GT (0.004) alkaline phosphatase (0.05), total cholesterol (P = 0.03), fasting glucose (P = 0.008), insulinemia (0.0006), HOMA value (0.002) and C-reactive protein (CRP; 0.04).
There was a significant reduction of IFN- , TNF- , and IL-6 (P = 0.02, 0.05 and 0.04, respectively).
The data suggest that the SPV complex exerts hepatoprotective, anti-inflammatory and antifibrotic effects. [Fibrosis is formation of bands of cyst-containing fibrous tissue.] This new compound may therefore be useful in clinical practice in patients with chronic hepatitis C who cannot undergo conventional antiviral therapy.
Source: Journal of Medical Virology, Nov 2008; 80(11), 1871-2052. PMID: 18814247, Falasca K, Ucciferri C, Mancino P, Vitacolonna E, De Tullio D, Pizzigallo E, Conti P, Vecchiet J. Clinic of Infectious Diseases, Department of Medicine and Science of Aging & Department of Oncology and Neuroscience, G. d’Annunzio University, Chieti-Pescara, Italy. [E-mail: firstname.lastname@example.org]